ES2206683T3 - Anticuerpos biotinalados que presentas una carga positiva neta reducida y una toxina, un farmaco o un quelato. - Google Patents

Anticuerpos biotinalados que presentas una carga positiva neta reducida y una toxina, un farmaco o un quelato.

Info

Publication number
ES2206683T3
ES2206683T3 ES97902867T ES97902867T ES2206683T3 ES 2206683 T3 ES2206683 T3 ES 2206683T3 ES 97902867 T ES97902867 T ES 97902867T ES 97902867 T ES97902867 T ES 97902867T ES 2206683 T3 ES2206683 T3 ES 2206683T3
Authority
ES
Spain
Prior art keywords
antibody
modified
antibodies
intact
lym
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97902867T
Other languages
English (en)
Spanish (es)
Inventor
Leslie A. Khawli
Alan L. Epstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Techniclone Inc
Original Assignee
Techniclone Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Techniclone Inc filed Critical Techniclone Inc
Application granted granted Critical
Publication of ES2206683T3 publication Critical patent/ES2206683T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6893—Pre-targeting systems involving an antibody for targeting specific cells clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ES97902867T 1996-01-11 1997-01-06 Anticuerpos biotinalados que presentas una carga positiva neta reducida y una toxina, un farmaco o un quelato. Expired - Lifetime ES2206683T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58607596A 1996-01-11 1996-01-11
US586075 1996-01-11

Publications (1)

Publication Number Publication Date
ES2206683T3 true ES2206683T3 (es) 2004-05-16

Family

ID=24344206

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97902867T Expired - Lifetime ES2206683T3 (es) 1996-01-11 1997-01-06 Anticuerpos biotinalados que presentas una carga positiva neta reducida y una toxina, un farmaco o un quelato.

Country Status (10)

Country Link
EP (1) EP0873139B1 (enExample)
JP (2) JP2000503301A (enExample)
KR (1) KR100485240B1 (enExample)
AT (1) ATE249243T1 (enExample)
AU (1) AU730388B2 (enExample)
CA (1) CA2242750C (enExample)
DE (1) DE69724761T2 (enExample)
ES (1) ES2206683T3 (enExample)
RU (1) RU2219949C2 (enExample)
WO (1) WO1997025069A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005047903A1 (en) * 2003-11-07 2005-05-26 Upstate Usa. Inc. A method for generating antibody conjugates that preserves antigen recognition
US20150344580A1 (en) * 2012-06-05 2015-12-03 Eldar Kim Human Monoclonal Antibodies Against Human Chemokine Receptor CCR7
KR102090849B1 (ko) 2012-07-04 2020-03-19 에프. 호프만-라 로슈 아게 공유 결합된 항원-항체 접합체
EP2869837B1 (en) 2012-07-04 2016-09-14 F. Hoffmann-La Roche AG Anti-theophylline antibodies and methods of use
EP3339328A1 (en) * 2012-07-04 2018-06-27 F. Hoffmann-La Roche AG Anti-biotin antibodies and methods of use
JP6602304B2 (ja) 2014-01-03 2019-11-06 エフ．ホフマン−ラ ロシュ アーゲー 共有結合で連結されたヘリカー−抗ヘリカー抗体コンジュゲートおよびその用途
EP3089759B1 (en) 2014-01-03 2018-12-05 F. Hoffmann-La Roche AG Covalently linked polypeptide toxin-antibody conjugates
PL3089996T3 (pl) 2014-01-03 2021-12-13 F. Hoffmann-La Roche Ag Dwuswoiste przeciwciała przeciw haptenowi/przeciw receptorowi występującemu w barierze krew-mózg, ich kompleksy i ich zastosowanie jako przenośniki wahadłowe występujące w barierze krew-mózg

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753894A (en) * 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
FR2566271B1 (fr) * 1984-06-20 1986-11-07 Sanofi Sa Nouveaux conjugues cytotoxiques utilisables en therapeutique et procede d'obtention
WO1988007553A1 (fr) * 1987-03-26 1988-10-06 Teijin Limited Procede de preparation d'un complexe d'anticorps
EP0593452A1 (en) * 1989-11-30 1994-04-27 Mallinckrodt Medical, Inc. Method for preparing a metal-radionuclide-labelled protein
US5194594A (en) * 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
SE9100142L (sv) * 1991-01-17 1992-07-18 Bengt Sandberg En metod och ett system foer foerbaettrad in vivo reducering av diagnostiska och/eller terapeutiska substanser medelst extrakorporeal borttagning, och anvaendandet av naemnda substanser foer detta aendamaal
US5578287A (en) * 1992-06-09 1996-11-26 Neorx Corporation Three-step pretargeting methods using improved biotin-active agent
DE69331319T2 (de) * 1992-06-09 2002-08-08 Neorx Corp., Seattle Biotin-DOTA Konjugate und deren Verwendung in "Pretargeting" Verfahren
JPH0853499A (ja) * 1994-08-10 1996-02-27 Green Cross Corp:The キメラ抗体Ｆａｂ断片のオリゴマー体

Also Published As

Publication number Publication date
AU1693997A (en) 1997-08-01
DE69724761D1 (de) 2003-10-16
ATE249243T1 (de) 2003-09-15
KR19990077198A (ko) 1999-10-25
DE69724761T2 (de) 2004-08-05
CA2242750A1 (en) 1997-07-17
CA2242750C (en) 2007-03-27
JP2012131808A (ja) 2012-07-12
KR100485240B1 (ko) 2006-10-24
JP2000503301A (ja) 2000-03-21
EP0873139B1 (en) 2003-09-10
WO1997025069A1 (en) 1997-07-17
EP0873139A1 (en) 1998-10-28
AU730388B2 (en) 2001-03-08
RU2219949C2 (ru) 2003-12-27

Similar Documents

Publication Publication Date Title
US5990286A (en) Antibodies with reduced net positive charge
JP3936339B2 (ja) 調節された浄化時間を有する修飾抗体
US6096289A (en) Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
Goodwin et al. Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens
US5716595A (en) Intraperative, intravascular and endoscopic tumor and lesion detection and therapy with monovalent antibody fragments
ES2769538T3 (es) Kit de predireccionamiento, método y agentes que se usan en éste
Sarrett et al. Inverse electron demand Diels–Alder click chemistry for pretargeted PET imaging and radioimmunotherapy
ES2364811T3 (es) Conjugados de unión con un re.
JPH05502236A (ja) 感染性及び炎症性病変の検出及び治療のためのキメラ抗体
ES2201309T3 (es) Terapia por captura de neutrones de boro utilizando procedimientos de direccionamiento previo.
US5059413A (en) Scintigraphic monitoring of immunotoxins using radionuclides and heterobifunctional chelators
ES2794581T3 (es) Procedimientos y kits para preparar complejos de radionúclidos
JP2012131808A (ja) 減少した正味の正電荷を有する抗体
Ballou et al. Tumor radioimmunolocation: differential antibody retention by antigenic normal tissue and tumor.
ES2625815T3 (es) Avidina oxidada con alto tiempo de residencia en los tejidos tratados
JP2004534752A (ja) 卵黄抗体（ｉｇｙ）からの免疫コンジュゲート、そのコンフェクショニングならびに診断および治療への使用方法
WO1997025069A9 (en) Antibodies with reduced net positive charge
Griffin et al. Initial clinical study of indium-111-labeled clone 110 anticarcinoembryonic antigen antibody in patients with colorectal cancer.
PT1135170E (pt) Radioconjugação de anticorpos de internalização
MXPA98005565A (en) Antibodies with positive reduced load
Haptens Pre-TargetedImmunoscintigraphyof Murine